 Blueprint Medicines Corporation  USA Stock   USD 64.21 0.72 1.11% 
Blueprint Medicines Corporation shows
Downside Deviation of 2.24,
Risk Adjusted Performance of 0.033 and
Mean Deviation of 1.82. Blueprint Medicines technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm future prices. In plain English you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum or the prices will eventually revert. We found nineteen
technical drivers for Blueprint Medicines Corporation which can be compared to its rivals. Please confirm
Blueprint Medicines Treynor Ratio as well as the
relationship between
Potential Upside and
Expected Short fall to decide if Blueprint Medicines is priced correctly providing market reflects its regular price of 64.21 per share. Given that Blueprint Medicines has
Jensen Alpha of
(0.27), we suggest you validate Blueprint Medicines Corporation prevailing market performance to make sure the company can sustain itself at future point.
Investment Horizon

30 Days
Login
to change

Blueprint Medicines Trend Analysis
Use this graph to draw trend lines for Blueprint Medicines Corporation. You can use it to identify possible trend reversals for Blueprint Medicines as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Blueprint Medicines price movement. To start drawing, click on the pencil icon on topright. To remove the trend, use eraser icon.
Blueprint Medicines Best Fit Change Line
The following chart estimates an ordinary least squares regression model for Blueprint Medicines Corporation applied against its price change over selected period. The best fit line has a slop of
0.34 % which may suggest that Blueprint Medicines Corporation market price will keep on failing further. It has 34 observation points and a regression sum of squares at 92.97, which is the sum of squared deviations for the predicted Blueprint Medicines price change compared to its average price change.
  Portfolio RebalancingAnalyze riskadjusted returns against different time horizons to find assetallocation targets 
Blueprint Medicines Corporation is rated
fifth in mean deviation category among related companies. It is currently under evaluation in standard deviation category among related companies creating about
1.23 of Standard Deviation per Mean Deviation. The ratio of Standard Deviation to Mean Deviation for Blueprint Medicines Corporation is roughly
1.23